Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NMR vs EVR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)

NMR Overall Winner 6-Pillar Tally: NMR 3 – 3 EVR Matrix Metrics: NMR 9 – 1 EVR

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Evercore Inc. (EVR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas EVR carries 40.2/100 (SELL) at $291.47 (13.7x Forward P/E, 22.1% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMR vs EVR
NMR NYSE Head-to-Head Winner
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.74% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68
EVR NYSE
Evercore Inc.
Investment Advice
$291.47
-0.23% 1D
Market Cap $11.3B
TTM Revenue $4.84B
Forward P/E 13.7x
Beta / 30D Vol 1.57β · 58% Vol
Unified Composite Score
40.2 / 100 SELL
Tech 36.0 Fund 47.0 Flow 65.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $285.31 · SMA50: $272.86

6-Pillar Scorecard Institutional Category Breakdown (NMR 3 – 3 EVR)

Columns: Metric · NMR · EVR
1. Valuation Multiples NMR
Forward P/E 12.7x 13.7x
Trailing P/E 11.2x 16.2x
PEG Ratio 0.81x 1.19x
EV / Revenue 1.9x 2.3x
2. Growth & Scale NMR
Revenue Growth (YoY) +17.9% +12.4%
Earnings Growth (YoY) +13.6% +15.2%
TTM Revenue (USD) $14.9B $4.84B
Market Cap $28.3B $11.3B
3. Profitability & Quality NMR
Gross Margin 77.4% 93.7%
Operating Margin 25.1% 22.1%
Net Profit Margin 17.1% 15.7%
Return on Equity (ROE) 11.5% 38.0%
4. Balance Sheet & Cash Flow EVR
Cash Generation (TTM) N/A $1.73B
Cash Flow Margin N/A 35.7%
Net Cash / Leverage $8.17 Book/Sh · 11.5% ROE $260M Net Cash
Dividend Yield 3.34% 1.19%
5. Options & Positioning EVR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 30.7% (<1st %ile) 53.8% (11th %ile)
Put/Call OI Skew Thin ADR Chain 16.83x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat EVR
OpEx & R&D Intensity 52.3% of Rev ($7.77B) 71.6% of Rev ($3.46B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Capital Markets Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMR (9) vs EVR (1)
Institutional Metric NMR EVR Criterion Row Edge
Market Capitalization
Scale
$28.3B $11.3B Larger Scale NMR
Trailing P/E Ratio
Valuation
11.2x 16.2x Lower Multiple NMR
Forward P/E Ratio
Valuation
12.7x 13.7x Lower Multiple NMR
Revenue Growth (YoY)
Growth
+17.9% +12.4% Higher Growth NMR
Operating Margin (TTM)
Profitability
25.1% 22.1% Higher Margin NMR
Net Profit Margin
Profitability
17.1% 15.7% Higher Margin NMR
Return on Equity (ROE)
Capital Efficiency
11.5% 38.0% Higher ROE EVR
52-Week Range Position
Momentum
60% ($7–$11) 32% ($245–$389) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
1.03β · 29% Vol 1.57β · 58% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 40.2 / 100 (SELL) Higher Composite NMR
Trailing 12M Revenue (USD)
Operating Scale
$14.9B $4.84B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.4% 93.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 1.9x EV/Rev 1.19x PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.17 Book/Sh · 11.5% ROE) $1.73B ($260M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVR +15.19 pp
NMR: +2.36% · EVR: +17.55%
3M Horizon NMR +0.48 pp
NMR: -1.84% · EVR: -2.32%
6M Horizon NMR +26.52 pp
NMR: +16.69% · EVR: -9.83%
1Y Horizon NMR +31.61 pp
NMR: +26.32% · EVR: -5.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs EVR. Trailing 12-month operating profitability (NMR 25.1% vs EVR 22.1%) and valuation multiples (NMR 12.7x vs EVR 13.7x Forward P/E) are benchmarked directly in Pillar 4 below.

NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x
EVR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.84B
Gross Margin93.7%
Op. Margin22.1%
ROE / Fwd P/E38.0% · 13.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVR CONSOLIDATION
148d in phase · OBV NEUTRAL
Current IV 53.8%
IV Percentile 11th %ile
Put/Call OI Skew 16.83x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact EVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published
EVR Moat Profile High-Margin Pricing Power Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $11.3B market capitalization and 22.1% operating margin.
OpEx & R&D Reinvestment 71.6% of Rev ($3.46B)
90D Engineering Disclosures 0 Published

Investor FAQ NMR vs EVR Key Questions & Quantitative Answers

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Evercore Inc. (EVR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas EVR carries 40.2/100 (SELL) at $291.47 (13.7x Forward P/E, 22.1% operating margin). Technically, NMR sits in a Neutral phase (RSI 45.5, UNCLASSIFIED options structure) and EVR sits in a Neutral phase (RSI 54.5, CONSOLIDATION options structure).

NMR leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with EVR at +12.4% YoY revenue growth and +15.2% YoY earnings growth on $4.84B TTM revenue (93.7% gross margin, 22.1% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $4.84B for EVR. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 71.6% of Rev ($3.46B) (0 disclosures) for EVR.

NMR screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas EVR trades at 13.7x Forward P/E, 16.2x Trailing P/E, 1.19x PEG, and 2.3x EV/Revenue (35.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus EVR (38.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, EVR carries 53.8% implied volatility (11th %ile, Compressed (<25th %ile)), a 16.83x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.